BAJAJ BROKING

Notification close image
No new Notification messages
card image
Seshaasai Technologies Ltd IPO
Apply for the Seshaasai Technologies Ltd IPO through UPI in Just minutes
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image
Active
Mainboard

Corona Remedies Ltd

Apply Now

Corona Remedies Ltd IPO Details

Listing Date

15 Dec 2025

Bid Price

₹1008 - ₹1,062

Lot Size

14 Shares

Minimum Investment

₹14,868 / Lot

Issue Size

₹655.37 Crores

Employee Discount

₹54 per share

IPO Doc

DRHP PDF pdf

Schedule

    Here are the important dates you need to know in order to participate in this IPO

tick

Bidding starts

8th Dec

tick

Bidding ends

10th Dec

tick

Allotment of shares

11th Dec

tick

Initiation of refund

12th Dec

tick

Credit of shares to Demat account

12th Dec

tick

Listing date

15th Dec

About Corona Remedies Ltd IPO

Incorporated in August 2004, Corona Remedies Limited operates as a pharmaceutical company with activities in the development, manufacturing, and marketing of branded formulations. The company’s product portfolio covers multiple therapeutic segments, including women’s healthcare, cardio-diabeto, pain management, urology, and other multispecialty areas. As of June 30, 2025, the portfolio consisted of 71 brands across these categories, including products in vitamins and minerals, nutrition, gastrointestinal, and respiratory segments. The company engages with healthcare professionals through a marketing and distribution network present across 22 states, supported by 2,671 medical representatives. This network is positioned to facilitate product availability in different regions of the Indian pharmaceutical market.
 

Corona Remedies Limited operates two manufacturing facilities located in Gujarat, with a reported aggregate installed formulation capacity of 1,285.44 million units per annum. Based on available domestic sales data for MAT June 2025, the women’s healthcare segment accounted for 28.56% of sales at ₹4,080.26 million, cardio-diabeto products accounted for 23.38% at ₹3,339.96 million, pain management contributed 11.79% at ₹1,684.38 million, and the urology segment accounted for 4.53% at ₹646.65 million. These figures reflect the contribution of individual therapeutic segments within the company’s product basket. The information provided reflects publicly available disclosures and can be cross-checked with official filings for accuracy.

Shareholder Pattern

  Pre-Issue Post-Issue
Promoter Group 72.5% 69%
Public Group 27.5% 31%

Corona Remedies Ltd IPO Reservation

QIB Shares Offered 12,23,203 (19.82%)
NII (HNI) Shares Offered 9,17,403 (14.87%)
Retail Shares Offered 21,40,606 (34.69%)
Anchor Investor Shares Offered 18,34,805 (29.73%)
Total Shares Offered 61,71,102
Total Shares With Anchor Investor 61,71,102

Corona Remedies Ltd IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 14 ₹14,868
Retail (Max) 13 182 ₹1,93,284
S HNI (Min) 14 196 ₹2,08,152
S HNI (Max) 67 938 ₹9,96,156
B HNI (MIN) 68 952 ₹10,11,024

Corona Remedies Ltd IPO Anchor Investor Details

Bid Date December 05, 2025
Shares Offered 19,59,116
Anchor Investment Details 208.0581192

Corona Remedies Ltd IPO registrar

Bigshare Services Pvt Ltd
Phone Number +91 22626 38200
Email Id investor@bigshareonline.com
Website www.bigshareonline.com

Corona Remedies Ltd IPO Lead Manager

1. JM Financial Ltd

2. IIFL Capital Services Ltd

3. Kotak Mahindra Capital Co. Ltd

Corona Remedies Ltd Financial Information

March 31, 2025 March 31, 2024 March 31, 2023
Net Worth ₹606.34 cr ₹480.41 cr ₹408.52 cr
Reserves and Surplus ₹545.18 cr ₹419.25 cr ₹347.36 cr
Total Borrowing ₹62.69 cr ₹134.14 cr ₹2.33 cr

Corona Remedies Ltd IPO Subscription LIVE Status

Category No. of shares offered No. of shares bid No. of subscribed
Qualified Institutional Buyers (QIBs) 0 0 0
Non Institutional Investors (NIIs) 0 0 0
NII(Bid amount of more than Ten Lakh Rupees) 0 0 0
NII(Bid amount of more than 2 Lakh < 10 Rupees) 0 0 0
Retail Individual Investors (RIIs) 0 0 0
Total 0 0 0

Strength of Corona Remedies Ltd

  • Second fastest growing company within the top 30 pharmaceutical companies in the Indian pharmaceutical market by domestic sales between MAT June 2022 and MAT June 2025.
  • Demonstrated capabilities of building a diversified portfolio, including "engine" brands, in our targeted therapy areas.
  • Pan-India sales network and marketing strategy focused on the "middle of the pyramid" target market.
  • Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities driving a portfolio of differentiated pharmaceutical products.
  • Qualified, experienced and entrepreneurial management team supported by marquee investors.

Risks Involved

  • The therapeutic areas of women's healthcare, cardio-diabeto and pain management contributed to an aggregate of Rs.2,257.26 million (or 65.14%) and Rs.7,465.54 million (or 62.40%) of our revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025, respectively. If our products in these or other therapeutic areas which contribute significantly to our revenue from operations do not perform as expected or if competing products become available and gain wider market acceptance, our business, results of operations, financial condition and cash flows may be adversely affected.
  • Our 27 "engine" brands (and in particular, our B-29 and Myoril brands) accounted for 72.34% of our domestic sales during the MAT June 2025 period, and any adverse developments affecting the sales of our "engine" brands could have an adverse effect on our business, results of operations, financial condition and cash flows.
  • The company derive a significant majority of its revenue from the company operations within India (constituting 96.34% and 96.33% of the company revenue from operations during the three months ended June 30, 2025 and the Financial Year 2025, respectively). In the event of a fall in demand for the company products in India, or if its fail to successfully expand into international markets, the company business, results of operations, financial conditions and cash flows may be adversely affected.
  • A significant portion of the company domestic sales are concentrated in the states of Gujarat, Maharashtra, Chhattisgarh, Goa and Madhya Pradesh (accounting for 47.30% of the company domestic sales for MAT June 2025). Any adverse developments affecting its sales in these regions could has an adverse effect on the company business, results of operations, financial condition and cash flows.
  • 70.10% of Its domestic sales for MAT June 2025 were derived from chronic and sub-chronic therapeutic segments, which are subject to risks and uncertainties that could adversely affect the company business, results of operations, financial condition and cash flows.
  • Its depend on third-party suppliers to procure the company raw materials and finished goods, with whom the company does not has long term contracts, with the company total purchases aggregating to 19.87% and 27.96% of its total expenses for the three months ended June 30, 2025 and the Financial Year 2025, respectively. Further, the company rely on La Chandra Pharmalab Private Limited, its Associate and Group Company, for the supply of certain active pharmaceutical ingredients in the comapny women's healthcare therapeutic area. its cannot assure you that the company will be in a position to fully control or direct the operations of such suppliers to ensure an uninterrupted supply of raw materials and APIs.
  • As of June 30, 2025, with a portfolio of 71 brands, its held 194 registered trademarks, with 29 pending trademark applications and 67 opposed/ objected/ refused / abandoned trademarks under certain classes of trademarks. If its unable to obtain trademarks for the company products and brands or protect other proprietary information, the company business, results of operations, financial condition and cash flows may be adversely affected.
  • The company required to obtain, maintain or renew its statutory and regulatory licenses, permits and approvals required to operate the company operations. If its fail to obtain, maintain or renew the required licenses, permits and approvals, it may adversely affect the company business, results of operations, financial condition and cash flows.
  • Proceeds from the Offer will not be available to it.
  • As of June 30, 2025, its engaged 22 carrying and forwarding agents for the sale of the company products across the regions in which the company market its products, with the company five largest C&F agents contributing to 43.30% and 44.35% of Its revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025. The loss of the company C&F agents, the deterioration of their financial condition or prospects, a reduction in their demand for the company products or its inability to maintain and increase the number of the company arrangements for the distribution of its products could adversely affect the company business, results of operations, financial conditions and cash flows.
stock

Invest in IPOs with ease

Sign-in to invest with your demat account, or set up a new demat account for free

Industry Outlook of Corona Remedies IPO

  • The Indian domestic formulation segment in Financial Year 2025 reported an estimated market value of around ₹2.3 trillion, representing close to 2% of the global pharmaceutical market size.

  • The sector operates within a manufacturing ecosystem that includes production facilities with advanced technology and a specialised workforce engaged in pharmaceutical development.

  • Consumption within the domestic formulation market recorded a compound annual growth rate (CAGR) of about 9% during Financial Years 2020 to 2025, based on available sector data.

  • Market projections sourced from industry estimates indicate a possible CAGR range of 8–9% for the period leading to Financial Year 2030.

  • The estimated value range for the market by Financial Year 2030 has been placed between ₹3.3 trillion and ₹3.5 trillion in published assessments.

  • These projections reflect demand factors that include higher reported cases of long-duration health conditions, rising awareness levels, and wider access to healthcare services in India.


Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your IPO allotment status for Corona Remedies IPO.    

Explore Other IPOs

  • Current IPOs
  • Upcoming IPOs
  • Closed IPOs
  • IPO Performance
  • All
  • MainBoard
  • SME
Nephrocare Health Services Limited IPO
Bidding Period
10th Dec 2025 - 12th Dec 2025
Price Range
₹438.0 - 460.0
IPO Size
₹8,71,05,00,000
Park Medi World Limited IPO
Bidding Period
10th Dec 2025 - 12th Dec 2025
Price Range
₹154.0 - 162.0
IPO Size
₹9,20,00,00,000
Shipwaves Online Limited IPO
Bidding Period
10th Dec 2025 - 12th Dec 2025
Price Range
₹12.0 - 12.0
IPO Size
₹56,35,00,000
Unisem Agritech Limited IPO
Bidding Period
10th Dec 2025 - 12th Dec 2025
Price Range
₹63.0 - 65.0
IPO Size
₹21,45,00,000
Pajson Agro India Limited IPO
Bidding Period
11th Dec 2025 - 12th Dec 2025
Price Range
₹112.0 - 118.0
IPO Size
₹74,45,00,000
Ashwini Container Movers Limited IPO
Bidding Period
12th Dec 2025 - 12th Dec 2025
Price Range
₹135.0 - 142.0
IPO Size
₹71,00,00,000
Neptune Logitek Limited IPO
Bidding Period
15th Dec 2025 - 12th Dec 2025
Price Range
₹126.0 - 126.0
IPO Size
₹46,62,00,000
Aarvee Engineering Consultants Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aastha Spintex Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advanced SysTek Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Advit Jewels Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Aggcon Equipments International Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Agilus Diagnostics Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Airox Technologies Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Ajay Poly Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alcobrew Distilleries India Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allchem Lifescience Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Allied Engineering Works Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Alpine Texworld Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
Amagi Media Labs Limited IPO
Bidding Period
To Be Announced
Price Range
₹0.0 - 0.0
IPO Size
₹0
NO ACTIVE IPO HERE
  • All
  • MainBoard
  • SME
AEQUS LIMITED IPO
Bidding Period
3rd Dec 2025 - 12th Dec 2025
Price Range
₹118.0 - 124.0
IPO Size
₹9,21,81,00,000
MEESHO LIMITED IPO
Bidding Period
3rd Dec 2025 - 12th Dec 2025
Price Range
₹105.0 - 111.0
IPO Size
₹54,21,20,00,000
SHRI KANHA STAINLESS LIMITED IPO
Bidding Period
3rd Dec 2025 - 12th Dec 2025
Price Range
₹90.0 - 90.0
IPO Size
₹46,28,00,000
VIDYA WIRES LIMITED IPO
Bidding Period
3rd Dec 2025 - 12th Dec 2025
Price Range
₹48.0 - 52.0
IPO Size
₹3,00,01,00,000
NEOCHEM BIO SOLUTIONS LIMITED IPO
Bidding Period
2nd Dec 2025 - 12th Dec 2025
Price Range
₹93.0 - 98.0
IPO Size
₹44,97,00,000
HELLOJI HOLIDAYS LIMITED IPO
Bidding Period
2nd Dec 2025 - 12th Dec 2025
Price Range
₹110.0 - 118.0
IPO Size
₹10,96,00,000
ASTRON MULTIGRAIN LIMITED IPO
Bidding Period
1st Dec 2025 - 12th Dec 2025
Price Range
₹63.0 - 63.0
IPO Size
₹18,40,00,000
CLEAR SECURED SERVICES LIMITED IPO
Bidding Period
1st Dec 2025 - 12th Dec 2025
Price Range
₹125.0 - 132.0
IPO Size
₹85,60,00,000
RAVELCARE LIMITED IPO
Bidding Period
1st Dec 2025 - 12th Dec 2025
Price Range
₹123.0 - 130.0
IPO Size
₹24,10,00,000
INVICTA DIAGNOSTIC LIMITED IPO
Bidding Period
1st Dec 2025 - 12th Dec 2025
Price Range
₹80.0 - 85.0
IPO Size
₹28,12,00,000
SPEB ADHESIVES LIMITED IPO
Bidding Period
1st Dec 2025 - 12th Dec 2025
Price Range
₹52.0 - 56.0
IPO Size
₹33,73,00,000
LOGICIEL SOLUTIONS LIMITED IPO
Bidding Period
28th Nov 2025 - 12th Dec 2025
Price Range
₹183.0 - 193.0
IPO Size
₹36,30,00,000
PURPLE WAVE INFOCOM LIMITED IPO
Bidding Period
28th Nov 2025 - 12th Dec 2025
Price Range
₹120.0 - 126.0
IPO Size
₹31,45,00,000
EXATO TECHNOLOGIES LIMITED IPO
Bidding Period
28th Nov 2025 - 12th Dec 2025
Price Range
₹133.0 - 140.0
IPO Size
₹37,45,00,000
MOTHER NUTRI FOODS LIMITED IPO
Bidding Period
26th Nov 2025 - 11th Nov 2025
Price Range
₹111.0 - 117.0
IPO Size
₹39,59,00,000
K K SILK MILLS LIMITED IPO
Bidding Period
26th Nov 2025 - 11th Nov 2025
Price Range
₹36.0 - 38.0
IPO Size
₹28,50,00,000
SSMD AGROTECH INDIA LIMITED IPO
Bidding Period
25th Nov 2025 - 11th Nov 2025
Price Range
₹114.0 - 121.0
IPO Size
₹33,80,00,000
SUDEEP PHARMA LIMITED IPO
Bidding Period
21st Nov 2025 - 11th Nov 2025
Price Range
₹563.0 - 593.0
IPO Size
₹8,95,00,00,000
EXCELSOFT TECHNOLOGIES LIMITED IPO
Bidding Period
19th Nov 2025 - 11th Nov 2025
Price Range
₹114.0 - 120.0
IPO Size
₹5,00,00,00,000
GALLARD STEEL LIMITED IPO
Bidding Period
19th Nov 2025 - 11th Nov 2025
Price Range
₹142.0 - 150.0
IPO Size
₹37,50,00,000
  • All
  • MainBoard
  • SME
LOGICIEL SOLUTIONS LIMITED IPO
Issue Prize
193.00
Listing Day Close
146.70(-23.83%)
PURPLE WAVE INFOCOM LIMITED IPO
Issue Prize
126.00
Listing Day Close
130.50(3.97%)
EXATO TECHNOLOGIES LIMITED IPO
Issue Prize
140.00
Listing Day Close
279.30(99.29%)
MOTHER NUTRI FOODS LIMITED IPO
Issue Prize
117.00
Listing Day Close
124.30(5.98%)
K K SILK MILLS LIMITED IPO
Issue Prize
38.00
Listing Day Close
30.40(-21.05%)
SSMD AGROTECH INDIA LIMITED IPO
Issue Prize
121.00
Listing Day Close
76.65(-36.36%)
SUDEEP PHARMA LIMITED IPO
Issue Prize
593.00
Listing Day Close
773.70(30.52%)
EXCELSOFT TECHNOLOGIES LIMITED IPO
Issue Prize
120.00
Listing Day Close
125.95(5.00%)
GALLARD STEEL LIMITED IPO
Issue Prize
150.00
Listing Day Close
234.25(56.00%)
CAPILLARY TECHNOLOGIES INDIA LIMITED IPO
Issue Prize
577.00
Listing Day Close
606.90(5.20%)
FUJIYAMA POWER SYSTEMS LIMITED IPO
Issue Prize
228.00
Listing Day Close
208.35(-8.77%)
TENNECO CLEAN AIR INDIA LIMITED IPO
Issue Prize
397.00
Listing Day Close
491.20(23.68%)
EMMVEE PHOTOVOLTAIC POWER LIMITED IPO
Issue Prize
217.00
Listing Day Close
219.05(0.92%)
MAHAMAYA LIFESCIENCES LIMITED IPO
Issue Prize
114.00
Listing Day Close
116.00(1.75%)
PHYSICSWALLAH LIMITED IPO
Issue Prize
109.00
Listing Day Close
155.20(42.20%)
PINE LABS LIMITED IPO
Issue Prize
221.00
Listing Day Close
251.30(13.57%)
CURIS LIFESCIENCES LIMITED IPO
Issue Prize
128.00
Listing Day Close
141.00(10.16%)
SHINING TOOLS LIMITED IPO
Issue Prize
114.00
Listing Day Close
98.80(-13.16%)
FINBUD FINANCIAL SERVICES LIMITED IPO
Issue Prize
142.00
Listing Day Close
164.85(16.20%)
BILLIONBRAINS GARAGE VENTURES LIMITED IPO
Issue Prize
100.00
Listing Day Close
130.94(31.00%)

Frequently Asked Questions

What is Corona Remedies Ltd IPO?

Answer Field

Corona Remedies Ltd IPO is a Mainboard IPO of 61,71,102 equity shares of a face value of ₹10 aggregating up to ₹655.37 Crores. The issue is priced at ₹1008 to ₹1062 per share. The minimum order quantity is 14 Shares. The IPO opens on December 08, 2025, and closes on December 10, 2025. Bigshare Services Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE,NSE.

When Corona Remedies Ltd IPO will open?

Answer Field

The Corona Remedies Ltd IPO opens on December 08, 2025 and closes on December 10, 2025.

What is the lot size of Corona Remedies Ltd?

Answer Field

Corona Remedies Ltd lot size is 14 shares, and the minimum amount required is ₹14,868.

How to apply for Corona Remedies Ltd IPO?

Answer Field

You can apply in Corona Remedies Ltd IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. To apply for an IPO:

• Login to Bajaj Broking account App/Website & click on IPO

• Enter the number of lots and price at which you wish to apply.

• Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.

• You will receive a mandate notification to block funds in your UPI app.

• Approve the mandate request on your UPI and funds will be blocked.

When is Corona Remedies Ltd IPO allotment?

Answer Field

The finalization of Basis of Allotment for Corona Remedies Ltd IPO will be done on December 11, 2025, and the allotted shares will be credited to your demat account by December 12, 2025.

When is Corona Remedies Ltd IPO listing date?

Answer Field

The Corona Remedies Ltd listing date is December 15, 2025.

Who is the registrar of Corona Remedies Ltd IPO?

Answer Field

The registrar of Corona Remedies Ltd IPO is Bigshare Services Pvt Ltd

Which company is the book-running lead manager of the IPO?

Answer Field

JM Financial Ltd,IIFL Capital Services Ltd,Kotak Mahindra Capital Co. Ltd will be the book-running lead manager of this IPO.

What is the fresh issue of Corona Remedies Ltd IPO?

Answer Field

The fresh issue size is ₹[-] Crores equity shares.

What minimum lot size can retail subscribers subscribe to Corona Remedies Ltd?

Answer Field

Retail investors can subscribe to a minimum of one lot, 14 shares and ₹14,868 amount.

How can I approve the UPI mandate request for Corona Remedies Ltd IPO?

Answer Field

To apply for Corona Remedies Ltd IPO, you need to log in to your demat account to complete the bidding process. Then, approve the payment mandate on your UPI app.

What is the price range of Corona Remedies Ltd?

Answer Field

The price of each Corona Remedies Ltd share will be ranging in between ₹1008 to ₹1062 per share.

What is the cut-off time for the UPI mandate for Corona Remedies Ltd IPO?

Answer Field

The cut-off time for the UPI mandate confirmation is 5:00 PM, December 10, 2025.

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|